Drug intelligence / Profile preview

EI-4

Development stage
Preclinical
Lead developer
Liu, Guijun
Modality
Small Molecules
01

Overview

EI-4 is a novel small molecule inhibitor that targets the transcription factor ETS-1 (E26 transformation specific sequence 1). ETS-1 is a key regulator involved in the proliferation and invasion of malignant tumor cells, particularly in hepatocellular carcinoma (HCC), by mediating the transcription of invasion/migration-related factors like matrix metalloproteinases (MMPs). EI-4 has demonstrated the ability to inhibit ETS-1 transcription factor activation and suppress the proliferation and invasion of HCC cells, showing promising antitumor activity in preclinical studies. It was identified as part of a research effort to find new small molecule inhibitors of ETS-1 for HCC therapy.

Beyond the preview

Go deeper on EI-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EI-4.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call